Industry News
Pharmaceutical Industry News
Bayer has spent years working to…
Bayer has spent years working to get a handle on its Roundup legal mess. With a multibillion-dollar deal unveiled Tuesday, it's moving a step closer to that goal.
Shaped primarily by discussions…
Shaped primarily by discussions with Gen Xers and older millennials, a new campaign from a coalition formed by the CDC Foundation is using a familiar aesthetic to educate adults about managing high blood pressure.
The company is confident that…
The company is confident that results from a head-to-head trial against Regeneron's Eylea could make Axpaxli "one of the most consequential advances in retina," CEO Pravin Dugel, M.D., said in a statement. Investors were unimpressed,
Six years after the FDA approved…
Six years after the FDA approved Eli Lilly’s Retevmo to treat lung and thyroid cancers with a rare biomarker, the Indianapolis drugmaker is laying groundwork to move the treatment into the adjuvant setting, reporting the
Continuing the reinvention of its…
Continuing the reinvention of its cancer drug Gazyva as a treatment for immune-mediated diseases of the kidney—which resulted in a lupus nephritis nod last fall—Roche is touting new data that could tee up the antibody
Serving on Sanofi’s executive…
Serving on Sanofi's executive committee, Buxo will form part of Belén Garijo's leadership team when the outgoing Merck KGaA chief joins Sanofi as CEO at the end of April.
The clamor for radioisotopes has…
The clamor for radioisotopes has continued into the new year, with Novartis inking a deal with radiopharmaceutical producer Niowave to supply the pharma giant with the specialized ingredient Actinium-225 (Ac-225) used to develop targeted cancer
Vaccine Makers Curtail Research and Cut Jobs
Federal policies under Robert F. Kennedy Jr. that are hostile to vaccines have “sent a chill through the entire industry,” one scientist said.
Should Drug Companies Be Advertising to Consumers?
Aging means “becoming a target” of the industry, one expert said. After decades of debate, politicians of all stripes are proposing bans.
Determined to avoid a repeat of…
Determined to avoid a repeat of the supply shortfalls that plagued early GLP-1 rollouts for obesity, Eli Lilly has amassed a sizable store of its oral weight loss candidate orforglipron. Specifically, Lilly had secured “pre-launch
Friday’s RFI sets a March 19…
Friday’s RFI sets a March 19 deadline for stakeholders to weigh in on what the government should consider when putting together its second attempt at a 340B rebate test run.
A new campaign for Astellas…
A new campaign for Astellas Pharma’s Izervay is aimed at opening retina specialists’ eyes to the unique role they play in their geographic atrophy patients’ lives.
Vertex expects $500 million in…
Vertex expects $500 million in 2026 from new products outside of its flagship cystic fibrosis franchise. In 2025, those drugs delivered a combined total of $175.6 million.
The regulatory environment in the…
The regulatory environment in the United States encountered by Moderna during the development of its COVID-19 vaccine bears little resemblance to what the company experienced earlier this week when the FDA refused to review its
It’s déjà vu all over again….
It’s déjà vu all over again. Just as the IgA nephropathy space becomes increasingly crowded, Novartis aims to turn a statistical miss into a regulatory win.
Late Thursday, PTC revealed that…
Late Thursday, PTC revealed that it withdrew its FDA application for Translarna in nonsense mutation Duchenne muscular dystrophy after receiving feedback on its filing from the regulator.
Bayer has cooked up the next phase…
Bayer has cooked up the next phase of its “See Your Risks” campaign with celebrity chef Jeff Mauro. The drugmaker is offering people the chance to dine in Mauro’s immersive dark dining experience, the Heart
Senate Questions Health Care Firm for Profiting Off Program Meant for Poor
The program was meant to help hospitals provide for poor patients by offering drug savings. But critics say a Texas company has turned it into a big business, driving up costs for patients and insurers.
Eli Lilly and Innovent Biologics…
Eli Lilly and Innovent Biologics have deepened their ties with a new type of deal. China has indicted AstraZeneca and its former top exec in the country following investigations that emerged in 2024. Madrigal has
Novo plans to invest in an…
Novo plans to invest in an expansion of its facility in Athlone, Ireland, to produce its Wegovy pill for markets beyond the U.S., the company’s CEO, Mike Doustdar, told Bloomberg News in a newly published